Luis Alvarez | Source | Founder at Theradaptive

Our approach takes protein sequences that we discover using a lab-based test and optimizes them in several ways using our computational processes. For example, we can take a set of sequences which exhibit tight binding to a given implant material and make those sequences easier to manufacture, bind tighter, and able to survive terminal sterilization. We can also tune the strength of binding so that you can predict the release rate of the protein. This has allowed us to make protein therapeutics that stick to implants like a paint and make them bioactive.